VERAXA Biotech AG (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager program through a collaboration with ATUM. The partnership will apply ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines that support IND/CTA-enabling activities and future clinical development.
The announcement follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The cell line development is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
This development is important because it advances a novel approach to cancer immunotherapy that could address a key limitation of current T-cell engagers: off-target toxicity. By requiring two separate tumor targets for activation, the BiTAC platform aims to spare healthy tissues, which could lead to safer and more effective treatments. For patients, this could mean fewer side effects and the possibility of higher doses, potentially improving outcomes. For the industry, it represents a step forward in the design of bispecific antibodies, a rapidly growing class of cancer therapeutics.
The collaboration with ATUM, a leader in cell line engineering, is a critical step in bringing this technology from preclinical research to clinical development. The generation of stable cell lines is essential for producing consistent, high-quality material for regulatory filings and eventual clinical trials.
VERAXA Biotech AG, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), focuses on next-generation antibody-based therapeutics, including bispecific T-cell engagers and bispecific ADCs. The company's pipeline is built on transformative technologies and quality-by-design principles.
For more information, visit the company's newsroom at http://ibn.fm/VRXA.
